VLA‐1: a T cell surface antigen which defines a novel late stage of human T cell activation
- 1 January 1985
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 15 (5), 502-508
- https://doi.org/10.1002/eji.1830150515
Abstract
The VLA‐1 protein complex defines a previously undescribed very late stage of activated T cell differentiation, following either alloantigen or mitogen activation. This protein appears after 2–3 weeks of activation, considerably later than the early T cell activation antigens such as the interleukin 2 (IL2) receptor, transferrin receptor, 4F2 antigen, T10 and HLA‐DR, and has therefore been termed very late antigen‐1 (VLA‐1). Unlike the IL2 receptor, VLA‐1 expression does not require restimulation with antigen, and in fact, VLA‐1 expression was high on T cells that had lost their IL2 receptors. Expression of VLA‐1 was found on all or nearly all long‐term‐activated T cells including T4+ and T8+ clones, bulk cultures, long‐term T cells from adults and newborns and long‐term T cells maintained in pure or crude IL2 preparations. VLA‐1 was also found on HTLV‐1 infected T cell populations. Immunoprecipitation experiments confirmed that the VLA‐1 protein complex (210000/130000 Mr) can be co‐expressed with another protein complex called VLA‐2 (165 000/130 000 Mr) on the same T cell clones. However, co‐expression was not obligatory because in some long‐term cultures little or no VLA‐2 was present relative to VLA‐1. Because VLA‐1 defines a novel late stage of T cell activation, being present on all or most all types of long‐term activated T cells, and not on any other cell types in peripheral blood, it has unique potential as a marker for activated T cells in vivo and may provide a clue towards elucidating novel long‐term T cell functions or growth requirements of this late stage of T cell differentiation.This publication has 28 references indexed in Scilit:
- Genetic and biochemical characterization of human lymphocyte cell surface antigens. The A-1A5 and A-3A4 determinants.The Journal of Experimental Medicine, 1984
- Transient expression of interleukin 2 receptors. Consequences for T cell growth.The Journal of Experimental Medicine, 1983
- A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule.The Journal of Experimental Medicine, 1983
- A 55,000 Mr surface antigen on activated human T lymphocytes defined by a monoclonal antibodyHuman Immunology, 1983
- Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptorNature, 1983
- Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content.The Journal of Experimental Medicine, 1983
- A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptorNature, 1982
- Constitutive interleukin 2 production by the JURKAT human leukemic T cell lineEuropean Journal of Immunology, 1982
- Use of Monoclonal Anti-mouse Immunoglobulin to Detect Mouse AntibodiesHybridoma, 1981
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975